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Abstract: Human coronaviruses, especially SARS-CoV-2, are emerging pandemic infectious diseases
with high morbidity and mortality in certain group of patients. In general, SARS-CoV-2 causes symptoms
ranging from the common cold to severe conditions accompanied by lung injury, acute respiratory
distress syndrome in addition to other organs’ destruction. The main impact upon SARS-CoV-2 infection
is damage to alveolar and acute respiratory failure. Thus, lung cancer patients are identified as a
particularly high-risk group for SARS-CoV-2 infection and its complications. On the other hand, it has
been reported that SARS-CoV-2 spike (S) protein binds to angiotensin-converting enzyme 2 (ACE-2),
that promotes cellular entry of this virus in concert with host proteases, principally transmembrane
serine protease 2 (TMPRSS2). Today, there are no vaccines and/or effective drugs against the SARS-CoV-2
coronavirus. Thus, manipulation of key entry genes of this virus especially in lung cancer patients could
be one of the best approaches to manage SARS-CoV-2 infection in this group of patients. We herein
provide a comprehensive and up-to-date overview of the role of ACE-2 and TMPRSS2 genes, as key entry
elements as wel as therapeutic targets for SARS-CoV-2 infection, which can help to better understand the
applications and capacities of various remedial approaches for infected individuals, especially those
with lung cancer.
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1. Introduction
Lung cancer is the second most common malignancy in both men and women and accounts for
75–80% of cancer-related deaths, making it the leading cause of mortality worldwide [1]. Lung cancer
is a heterogeneous disease and can occur in various sites along the bronchial tree; based upon the
anatomical location different symptoms are present and classified into four types [2]. Tumors that rise in
the main bronchi and spreads to the carina are squamous cell lung cancers (SCC) and accounts for 25–30%
of all lung cancers, while those arising in the peripheral bronchi exhibit glandular morphology and are
classified as adenocarcinomas and account for 40% of all lung cancers [2]. Furthermore, tumors which
lack the classic glandular or squamous morphology but exhibit neuroendocrine differentiation are
classified as small-cell lung carcinomas (SCLC) and constitute ~15–20% of all lung carcinomas [2].
The remaining subtype without any of the afore-mentioned morphologies is called large cell carcinomas,
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some of which may also have neuroendocrine differentiation (Large cell neuroendocrine carcinomas).
SCC, adenocarcinomas and large cell carcinomas are usually categorized as non-small cell lung
carcinomas (NSCLC) as they have different pathological, molecular genetics and clinical characteristics
in comparison with SCLC. It is believed, that both genetic, as in family history and polymorphisms,
and environmental risk factors are responsible for lung cancer; smoking being the major risk factor for
this disease [3,4]. Several recent studies have highlighted infectious agents such as bacteria [5–7] and
viruses [8–11] as high-risk factors of the disease.
It is projected that at least 20% of all human cancers are attributed to microorganisms’ infections
including viral [12]; viruses are linked with the onset of both solid and hematological malignancies
in humans [13]. Some of the frequently linked oncoviruses with lung cancer include Epstein Barr
virus (EBV), hepatitis viruses B and C (HBV and HCV), and human papillomaviruses (HPVs) [8,9,11].
However, their causal relationship to lung cancer has not been established yet. Some other viruses
such as coronaviruses have been implicated in various respiratory diseases including pneumonia,
upper respiratory tract infections, severe acute respiratory syndrome (SARS) and Middle-East
respiratory syndrome (MERS) in addition to the recent coronavirus disease 2019 (COVID-19) [14–16].
However, the role of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in lung cancer
patients is still unclear. This review will focus on the mechanisms linking SARS-CoV-2 to cancer,
especially lung cancer and the potential clinical relevance of the various inhibitors of SARS-CoV-2.
2. SARS-CoV-2 and Its Key Entry Genes
During December 2019 in Wuhan, China, several patients were diagnosed with atypical pneumonia
and these infections were associated with a zoonotic origin [17,18]. The investigations determined
β-coronavirus as the causative agent leading to the identification of SARS-CoV-2 [19]. Genetic analysis
listed SARS-CoV-2 in the genus Betacoronavirus and subgenus Sarbecovirus (lineage B); confirming its
origin to the bat coronavirus (BatCoV RaTG13) [19]; it is supposedly linked to the bat and pangolin
coronavirus as wel as SARS-CoV [19,20]. Further analysis showed only a single amino acid difference
between SARS-CoV and the pangolin Coronavirus, suggesting a potential transitional host [21].
The coronavirus S protein consists of two functional domains; S1 is the receptor-binding domain
while, S2 contains functional elements and plays a role in membrane fusion [22]. One of the distinctive
features of the coronavirus S protein is that it consists of more than one proteolytic cleavage site;
the first known cleavage site is present at the S1/S2 boundary, while the other is in the S2 upstream of
the putative fusion peptide [23]. Once the spike glycoprotein cleaves, the S1 and S2 domains remain
linked non-covalently; this association remains after cleavage of spike glycoprotein, then the S1 domain
sheds itself from the S2 stalk domain of the protein [23–25].
The pathogenic mechanisms of SARS-CoV-2 are still poorly understood. At the cellular level,
the viral particles enter into the host epithelial cell of the respiratory tract via cellular recognition
using a metallopeptidase. Similar to SARS-CoV, SARS-CoV-2 uses angiotensin converting enzyme II
(ACE-2) for viral entry; ACE-2 is a cellular receptor and plays a role in the breakdown of angiotensin II
to regulate the renin–angiotensin system (RAS) [26]. The viral S protein combines with the ACE-2
receptor to enhance cellular membrane fusion and endocytosis; this process is dependent on S protein
and is modulated by type II transmembrane serine proteases (TTSPs) [27,28]. TTSPs, such as TMPRSS2
and TMPRSS11D, play critical roles in spike protein cleavage and activate SARS-CoV permitting
entry into the host by membrane fusion [29]. This indicates that TTSPs might play a principle role
in SARS-CoV-2 spread and infections. On the other hand, additional proteases are indicated in the
priming of SARS-CoV-2 but not SARS-CoV; one potential protease is FURIN [30]. Unlike SARS-CoV,
SARS-CoV-2 protein consists of four redundant FURIN cut sites (PRRA motif) [30]. The FURIN protease
allows effective cleavage of the SARS-CoV-2 protein [30], which upon receptor binding enhances viral
entry into the host cell [31,32].
The renin–angiotensin system (RAS) is known as one of the major regulatory systems for
maintaining blood pressure and body fluid homoeostasis [33]. ACE converts the inactive peptide
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hormone angiotensin I (Ang-I) to an active octapeptide, angiotensin II (Ang-II) [34,35]. Ang-II mediates
its biological effects by binding to two receptors, which belong to the G-protein coupled receptor
family, the angiotensin type I and type II receptors (AT1R and AT2R) [36]. While both receptors are
responsible for signal transduction, they result in opposing effects, with AT1R activation leading
to increased cell proliferation and vasoconstriction of blood vessels, while AT2R activation leads to
decreased cell proliferation and vasodilation [37]. Binding of Ang-II to specific receptors activates a
number of different events in various tissues and cell types [38]. In 2000, a homologue of ACE (ACE-2)
was identified in humans [39]. ACE-2 is a type 1 integral membrane zinc-metalloprotease glycoprotein
present in many cardiovascular-relevant organs, such as heart, kidneys, blood vessels, and lungs [40–42].
ACE-2 is also found in vascular smooth muscle cells, gastrointestinal tract, liver, pancreas, retina, central
nervous system, bone marrow, and lymphoid tissues although at lower levels when compared to
heart or kidneys (reviewed in [43,44]). ACE-2 is a key-regulator within the RAS and counteracts
with ACE in two ways: Either it metabolizes the vasoconstrictive and pro-inflammatory Ang (1-8)
directly to generate the vasodilatory and anti-proliferative Ang (1-7), a counter-regulatory enzyme
to ACE, or it competes for Ang (1-10) with ACE to form Ang (1-9), a precursor of Ang (1-7) [45].
Consequently, recognition of the two pathways of Ang (1-7) production via ACE-2, has opened a new
avenue to understand cardiovascular and lung physiology as wel as provide new potential targets and
therapeutic agents [39,46]. This was demonstrated by Mas knockout mice that have no antidiuretic
action of Ang (1-7) after an acute water load and whose aortas lose their angiotensin (1-7)-induced
relaxation response [47]. Ang (1-7) has the most promising therapeutic target due to its opposing
effects to Ang-II showing an anti-hypertensive, anti-hypertrophic, anti-fibrotic, and anti-thrombotic
properties [48]. However, therapeutic application of Ang (1-7) is limited due to its short half-life and
rapid turnover [49]. Hence, another approach of raising levels of Ang (1-7) is to increase the catalytic
activity or amount of ACE-2. Undoubtedly RAS is an intricate signaling system with numerous
possible ligands, receptors and ligand/receptor interactions that need to be investigated extensively.
Type II transmembrane serine proteases (TTSPs) is the largest group of membrane-anchored
serine proteases [50]. To date, nineteen human TTSps have been identified. TTSPs are classified into
four subfamilies including Hepsin/TMPRSS, Matriptase, HAT/DESC, and Corin [51]. Several different
isoforms exist in humans and rodents [51]; however, there are two non-mammalian TTSPs, Drosophila
stubble-stubbloid (st-sb) and corin [52,53]. The TMPRSS2 gene, also known as epitheliasin belongs to
the serine protease family that is located on human chromosome 21q22.3 and encodes a polypeptide
of 492 amino acids [54,55]. TMPRSS2 is 70-kDa and is almost 44kb in length with 14 exons that are
involved in various cellular processes including digestion, tissue remodeling, fertility, blood coagulation,
inflammatory responses, tumor cell invasion, and apoptosis [54,55]. While in-vitro translated TMPRSS2
protein is present as a zymogen with a molecular mass of around 54 kDa [56], the intrinsic and
recombinant human TMPRSS2 proteins undergo N-linked glycosylation and have a higher molecular
mass of approximately 60–70 kDa [56,57]. TMPRSS2 consists of five domains: Type II transmembrane,
low-density lipoprotein (receptor class A), scavenger receptor cysteine-rich, protease and cytoplasmic
domains [54]; however, the normal physiological role of TMPRSS2 is still unknown. Studies using
the Xenopus oocyte expression system revealed that TMPRSS2 expression reduced both the epithelial
sodium channel and protein levels [58].
3. Role of ACE-2 and TMPRSS2 in Lung Disease/COVID-19
ACE-2 expression is virtually present in all tissues with relatively higher expression in respiratory
epithelial cells, arteries, arterioles, and venules in the heart and kidney, alveolar cells type I and II,
oral cavity, testis, and intestines (6-8). Lung epithelial cells express high levels of ACE-2, which positively
correlates with airway epithelial differentiation [59]. ACE-2 is involved in pulmonary hypertension (PH)
and fibrosis [59]; and has been implicated in acute lung injury (ALI) by inducing an imbalance in RAS.
Evidence reveals that in ALI, supplementation with ACE-2 or inhibition of Ang-II improves outcomes
and that a decrease in pulmonary ACE-2 and increase in Ang-II levels aggravate viral-induced ALI [60].
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In addition to its role in cardiovascular physiology, ACE-2 is a receptor for the coronavirus linked to
SARS [61,62]. Surprisingly, involvement of ACE-2 in ARDS, which is triggered by multiple diseases
including SARS-CoV and SARS-CoV-2 infections, has been established in multiple animal models [63].
ACE-2 KO mice exhibit severe pathology of ARDS and age-related loss of ACE-2 in the lungs
correlates with increased mortality and worsened phenotype in elderly patients with COVID-19 [60,64].
Exogenous administration of ACE-2 in patients with ARDS did not show any difference in oxygenation
index or clinical outcomes, although there was a trend of decreasing IL-6 concentrations [65]. A recent
study showed that upregulation of ZEB1 reduced ACE-2 expression, which in turn downregulated
claudins, thus, increasing risk and pathogenesis of edema and ARDS in COVID-19 patients [66].
Collectively, these studies unequivocally establish the conceptual framework that ACE-2 is a central
player in normal pulmonary function, and its imbalance leads to pulmonary diseases.
On the other hand, in-situ analyses in humans and mice, showed that at both protein and mRNA
levels TMPRSS2 is expressed in the epithelia lining the salivary glands, gastrointestinal (stomach,
colon, small intestine and pancreas), urogenital (kidney, prostate and ovary), and respiratory tracts
including the bronchi and bronchioles, lung, but not in alveolar epithelium [67–70]. In prostate cells,
TMPRSS2 is a constituent of the normal seminal fluid and present in the secretory epithelium [68];
moreover, its expression is controlled by androgens in prostate cancer cells and tissues [56]. In parallel,
the expression of TMPRSS2 along with human airway trypsin-like protease (HAT) in the human lung
is demonstrated to support spread of the human influenza virus [71,72]. Furthermore, TMPRSS2
and TMPRSS4 stimulate hemagglutinin of the highly pathogenic 1918 influenza virus [73], indicating
the role of TTSPs in stimulating influenza virus in the human host. TMPRSS2 controls sodium
currents in lung epithelial cells through proteolytic cleavage of the epithelial sodium channel [58].
However, TMPRSS2 expression is inactivated via homologous recombination due to serine protease
domain disruption. Moreover, an in-vivo study in mice showed that TMPRSS2 deficiency did not
affect growth or survival of murine embryonic development with no anomalies in organ histology
and function [74]. Another study showed that TMPRSS2 depletion resulted in frailer, or delayed,
inflammatory chemokine and cytokine responses mediated by Toll-like receptor 3 (TLR3) [28].
Proteases are vital components of respiratory host defense; in the healthy lung they are involved
in regulating tissue homeostasis [75]. Along with serine proteases, cysteine proteases and matrix
metalloproteinases (MMPs) are dominantly present in the lung; enhanced activity of proteases is
linked with lung damage and the development of chronic lung diseases including emphysema and
chronic obstructive pulmonary disease (COPD) [76,77]. TMPRSS2 cleavage activity plays a vital role in
enhancing viral propagation of H7N9 influenza virus, H1N1 subtype influenza virus, SARS-CoV and
MERS-CoV [27,78–80]. TMPRSS2 stimulates influenza virus by cleaving hemagglutinin, indicating that
the enzyme can play a role in viral invasion of human airways [71,72]. Similarly, in the case of human
metapneumovirus (HMPV) which is responsible for bronchiolitis and pneumonia [81], TMPRSS2
stimulates the HMPV F protein allowing fusion and cleavage, thus enhancing virus propagation [82].
In-vivo study using mice lacking TMPRSS2 displayed suppressed or delayed inflammatory chemokine
and cytokine responses stimulated by TLR3 [83]. Activators of the cytokine response such as
interleukin-6 (IL–6), tumor-necrosis factor- α (TNF-α) and interferon- γ (IFN-γ) are involved in the
onset of ARDS and has been detected in severe COVID–19 patients [83].
In healthy individuals, when SARS-CoV-2 infects cells expressing ACE-2 and TMPRSS2,
active replication releases the virus resulting in pyroptosis, an inflammatory form of programmed
cell death [84]; the initial inflammatory response attracts virus-specific T cells to the site of infection,
where the infected cells are destroyed prior to virus spread, thus causing insignificant lung
damage. However, in immunocompromised patients, SARS-CoV-2-linked pyroptosis releases
damage-associated patterns (ATP, DNA, and ASC oligomers) which are recognized by neighboring
alveolar epithelial cells, endothelial cells and alveolar macrophages, stimulating release of
pro-inflammatory cytokines and chemokines (IL-6, IP-10, IL-1β, macrophage inflammatory protein
1 (MIP1α and MIP1β), TNF, and MCP1) into the blood of SARS-CoV-2-infected patients [17,85–87].
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These proteins attract monocytes, macrophages and T cells to the site of infection [88,89],
thus, stimulating inflammation and accumulation of immune cells in the lungs, causing further
production of pro-inflammatory cytokines thereby promoting lung damage [90] (Figure 1).
Uncontrolled inflammatory cell infiltration increases lung injury caused by SARS-CoV-2, resulting
in diffuse alveolar damage [88,89], thus, restricting gas exchange efficacy in lungs and affecting
blood oxygenation levels; thereby leaving the lungs highly prone to secondary infections [90].
Additionally, along with local damage, enhanced levels of cytokines induce septic shock and
multi-organ failure [91].
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action and tumor lung tissues. Activation of renin–angiotensin system c scade potentially leading to
angiotensinogen enzymatic cleavage to A giotensin I (An - I). Additionally, increase ACE abund nce
will potentially enhance producti n of the biologically active A g-II t at may lead to increase activation
of Angiotensin typ 1 receptor (AT1R) upon Ang-II binding. CE-2 converts Ang-I to Ang (1-7)
which acts through Mas receptor to protect from acute lung failure promoted through AT1R activation.
H wev r, i is still unknown how it may also nhance tumor development by stimulating vascularization.
On the other hand, the “spike” attachment protein for t current SARS-CoV-2 coronavirus uses the
cellula attachment factor, ACE-2 and requires TMPRSS2 cell prot ase for activation. This scena io
antagonizes the protective role of ACE-2 and thus leads to severe lung injury and acute lung failure.
Together, these pregulatio s have the potential t media e intracellular signaling pathways nd
stimulate the production of different cytoki es, inflammatory, an gr wth components such as
the for ation of transforming grow h fa tor (TGF)-β nd NF-κB to promote tumorigenesis and
epithelial–mesenchymal transit on (EMT) properti s including; proliferation, a giogenesis, fibrosis,
migration, and inv sion.
The pri ary site of SARS-CoV-2 infection is the hu an airway epitheliu [28]. Infection by
SARS-CoV results in loss of T PRSS2 expression in the airways and induces acute lung injury [28].
An in-vivo study showed the spread of SARS-CoV in an infected mouse was stimulated by TMPRSS2 [92].
Furthermore, another in-vivo study involving TMPRSS2-deficient mice, showed lack of CoV replication
in the lungs as wel as bronchioles [28]. However, in contrast, CoV spread and inflammatory infiltration
was observed in the alveoli in TMPRSS2-deficient mice; indicating the role of other serine proteases and
CatL in triggering SARS-CoV and MERS-CoV to migrate to alveolar areas [28]. In a very recent study,
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engineered kidney cell line, VeroE6/TMPRSS2 showed significant proneness to SARS-CoV-2 infection,
indicating a vital role of TMPRSS2 in SARS-CoV-2 [93]. During SARS-CoV-2, the insertion sequence
(680-SPRR-683) enhances TMPRSS2 cleavage activity, thus, increasing the viral infectivity [94]. A recent
study showed co-expression of TMPRSS2 and ACE-2 in the absorptive enterocytes, esophageal upper
epithelial cells and lung AT2 cells, suggesting a significant role of TMPRSS2 in COVID-19 infection [94].
As the interaction between coronaviruses and the host cell is mediated by binding of the viral
spike (S) protein to specific cell receptors of the host. This step is a major determinant of the viral
host and a tissue tropism. Structural studies were performed on different species revealing some
mechanisms of the SARS-CoV-2 use of cross-species receptor. The results indicate possible interspecies
transmission of SARS-CoV-2 and suggest additional surveillance in other animal populations [95].
In this regard, TMPRSS2 plays a vital role during viral entry, as the S protein of SARS-CoV
uses the endosomal cysteine proteases cathepsin B and L (CatB/L) for S protein priming in TMPRSS2
receptor [96]; however, priming of S protein by TMPRSS2 but not CatB/L is crucial for viral entry into
target cells and viral spread in the infected host [28,92]. Furthermore, TMPRSS2 cleaves SARS-S at
residue R667, which is significantly linked with the activation of SARS-S for cell to cell fusion [97];
R667 is frequently present in several cleavage motifs and is cleaved during S protein biogenesis [23].
Another residue, R797 is also vital for S protein activation by TMPRSS2 and is often cleaved during viral
entry [23]. A recent study indicated that the extra additional arginine residues linked structure projected
from the protein surface enhances the recognition and cleavage activity of TMPRSS2, thus, increasing
the viral infectivity of SARS-CoV-2 [94]. However, a few studies indicate presence of four inserts in the
S protein of SARS-CoV-2 due to artificial modification [94].
In a study by Lukassen et al. [98] RNA sequencing was used to analyze the expression of both
ACE-2 and TMPRSS2 in lung tissue and single cells obtained from normal subsegmental bronchial
branches and lung tissues that were resected from 16 patients with lung cancer (6 males and 10 females;
mean age ~50 years) [98]. The study reported a significant expression of ACE-2 in subsegmental
bronchial branches (in transient secretory cells) while TMPRSS2 was expressed in both lung tissues
and bronchial branches [98]. Intriguingly, these bronchial transient secretory cells were involved in
pathways related to RHO GTPase function and viral processes, indicating increased susceptibility
for SARS-CoV-2 infection. Although ACE-2 expression was not sex or age-dependent at a single
cell level, the authors found a trend for age dependency when all lung cell types are summed up
from female patients. The authors concluded that further larger studies involving both healthy and
infected patients of both sexes are required for a better understanding of vulnerability of different
age groups to SARS-CoV-2 [98]. Another study implicated the co-expression of TMPRSS2 and ACE-2
in the esophageal upper epithelial cells and lung AT2 cells, in COVID-19 infection [94]. A recent
investigation used the LungMAP website, GEPIA2 software and the lung cancer explorer (database
consisting of 6700 patients) to analyze ACE-2 and TMPRSS2 expression in lung development and lung
cancer, respectively [99]. However, the majority of those with upregulated ACE-2 expression were
more prone to developing COVID-19 disease [99].
A study by Pinto et al. [100] analyzed the expression of ACE-2 in more than 700 lung transcriptome
samples of patients with diseases including hypertension, diabetes, lung diseases (COPD or pulmonary
arterial hypertension) as wel as cancer; as compared to healthy individuals, ACE-2 was upregulated
in patients with comorbidities [100,101], indicating patients presenting with these disease are at
a higher risk of developing COVID-19. Furthermore, ACE-2 expression was higher in cancer as
compared to normal lung tissue [100]. In this study, network analyses identified several candidate
regulators of ACE-2 in the human lung; the majority of these genes were associated with histone
modifications as wel as epigenetic regulation of gene transcription (HAT1, HDAC2, and KDM5B) [100].
HAT and HDAC are involved in chromatin modification and DNA condensation, thus, allowing
gene transcription and upregulation of ACE-2 expression [100], indicating their role in lung disease
including COPD and lung cancer. Other genes included ADAM10 and TLR3; ADAM10 was found to
Cancers 2020, 12, 2186 7 of 21
regulate ACE2 cleavage in the human airway epithelia [102], while, TLR3 was involved in the innate
response to SARS-CoV or MERS-CoV infection [103].
4. Key Entry Genes of SARS-CoV-2 and Human Cancers Including Lung Cancer
A recent study analyzed the risk for developing COVID-19 in patients with cancer; they concluded
that these patients were at a higher risk of developing COVID-19 with poorer outcomes than individuals
without cancer [104]. Research into the link between the RAS and cancer has accelerated greatly over
the past years due to the growing evidence of local RAS signaling being deregulated in pathological
tissues and the prominent role for the angiotensin receptors in tissue remodeling. As a result of the
effects of ACE and the RAS as a whole, numerous studies have shown the association between ACE
function and metabolic diseases such as diabetes as wel as various cancers such as pancreatic and
breast cancer [105–107]. Thus, drugs used to target RAS might also prove effective against cancer.
There is a large body of evidence supporting the role of ACE-2 axis in disease and cancer [108–111].
The ACE-2 enzyme serves to counterbalance the effects of the ACE within the RAS [112]. Recent research
has begun to address whether the stimulation of ACE-2 function, or overexpression of ACE-2 in
diseased states is linked to positive effects [113]. Activation of the ACE-2 axis using Ang (1-7) in cancer
studies showed promising anticancer effects with disruption of growth-promoting signals as wel as
decreased angiogenesis, inflammation and metastasis of breast, prostate and hepatocellular carcinoma
cells [114,115]. ACE-2/Ang (1-7) axis overexpression has also been reported to inhibit cell proliferation
in pancreatic cancer cell lines, BxPC3 and SW1990, reduce epithelial–mesenchymal transition (EMT)
and inhibits the migration and invasion of non-small cell lung cancer (NSCLC) cells, A549 [116–118].
A recent study reported that downregulation of the ACE-2 axis promotes breast cancer cell metastasis
via increased calcium signaling [119]. In addition, the anticancer activity of Ang (1-7) has also been
described using in-vitro and in-vivo model systems [120–122]. Interestingly, it is suggested that upon
SARS-CoV binding to ACE-2 followed by cell entry and replication, ACE-2 is downregulated [123],
causing an imbalance between ACE/Ang-II/AT1R axis and ACE-2/Ang (1-7)/MasR axis. These events
can promote severe lung injury and acute lung failure as wel as enhance cancer pathogenicity through
several pathways [124,125]. In this regard, SARS-CoV-2-induced cell infection, promote molecular
changes, characterized by enhanced expression of ZEB1 and AXL, with comparatively reduced miR-200
levels and glutamine synthesis, indicating epithelial–mesenchymal transition, a key feature of cancer
onset and progression [66].
In human prostate and colon cancers, TMPRSS2 protein was found to be located on the apical
membrane of secretory epithelia as wel as in the lumen of the glands [56]. In prostate cancer, a protease
domain of around 32-kDa has been identified, indicating TMPRSS2 to be partly activated [56].
Similarly, TMPRSS2 mRNA expression is upregulated in androgen-activated prostate cancer cells [67];
elevated TMPRSS2 mRNA expression is suggested to be facilitated by the androgen receptor [56].
Furthermore, both in-vitro and in-vivo studies demonstrate treatment by androgen enhanced TMPRSS2
zymogen activation, thus implicating the role of TMPRSS2 in the onset and progression of prostate cancer
in an androgen-dependent manner [126]. Gene fusion between TMPRSS2 and members of the E26
transformation specific (ETS) transcription factor family (ERG or ETV) is another mechanism by which
TMPRSS2 plays a role in prostate cancer progression [127]. During gene fusion, the 5′-untranslated
region of TMPRSS2 is merged with the transcription factors, ERG or ETV genes which enhance
prostate cancer progression and invasion [128]. The most frequent gene fusion in prostate cancer is the
TMPRSS2–ERG gene fusion, which comprise around 50% of prostate cancers [128]. Molecular research
demonstrated dysregulated ERG expression to disrupt normal androgen receptor signaling and
trigger epigenetic pathways, thus promoting tumorigenesis [128]. The G-protein-coupled PAR-2
(protease-activated receptor-2) is expressed in prostate cancer cells [129–131]. TMPRSS2 stimulates
PAR-2 leading to upregulated levels of MMPs-2 and -9, thus, promoting inflammation, invasion,
and metastases [132,133].
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TMPRSS2 is also expressed in colon cancer, hepatocellular carcinoma [134], human nasal and
tracheal mucosa, distal airways, and lung [58,67,71,135]. Other TTPs are also involved in cancer;
while, TMPRSS4 is expressed in lung cancer tissue [136] and the human trachea [135], TMPRSS11D is
expressed in human bronchi and tracheae [135,137,138]. As compared to small-cell prostate carcinoma,
the TMPRSS2-ERG gene fusion is frequently absent in any small cell carcinoma of the urinary bladder
or lung; this can aid in differentiating small cell carcinoma of prostatic origin from non-prostatic
origins [139].
More specifically, vis-à-vis lung cancer and COVID-19, it is well-established that proteolytic
breakdown of the ECM components (collagens, laminins and elastin) result in severe lung damage
(164). Cancer patients are more likely to develop COVID-19 than the general population due to
malignancies-related chronic immunosuppressive and anti-cancer therapy [85,104]. Patients with
lung cancer are more susceptible to COVID–19 since they are typically smokers and old patients with
eventual occurrence of treatment-related immune deficiency [140–142]. Smokers increase their risk
of lung disease, including lung cancer, and are likely to be more vulnerable to COVID-19. It has
been shown that the histological changes and inflammation in ARDS resulted from smoking-induced
lung injury were presumably due to an irregular activation of ACE/ACE-2 pathway imbalance [63].
In order to study the role of ACE-2 in lung injury, a mouse model of induced lung injury by cigarette
smoke exposure for 1 to 3 weeks revealed that ACE-2 deficiency influences STAT3 phosphorylation and
MMPs activation to promote more pulmonary inflammation in the development of lung injury [143].
The ERK/MAPK/JNK signaling pathways are involved in regulating several processes including
cellular growth, proliferation, differentiation and apoptosis; which are important processes vital for
the onset and progression of tumors, including lung cancer [144–147].
Additionally, several studies reported phosphorylation of p38/ERK/JNK in SARS-CoV-infected Vero
E6 cells [148–150]; while, activated p38 has been indicated to play a role in lung cancer development [151].
Also, using SARS-CoV-2-transfected lung cancer cell line, A549, it was pointed out that SARS-CoV S protein,
or SARS-CoV virus-like particles, can activate ERK [152]. Similarly, cells transfected with MERS-CoV and
HCoV-229 also trigger the ERK pathway [153]. Moreover, upregulated expression of SARS-CoV S protein
in kidney cell line, 293T, can phosphorylate JNK via protein kinase C epsilon in a calcium-independent
pathway [154]. While, apoptosis induced by SARS-CoV N protein upregulation is JNK dependent [153],
JNK activation also stimulates IBV-induced apoptosis [155,156], indicating, a pro-apoptotic role of JNK
during early SARS-CoV infection and a pro-survival role in continual SARS-CoV-infected cells.
The clinical aspects of cancer patients with COVID-19 have remained relatively unknown until
now. Considering the related clinical symptoms of lung cancer such as fever, cough, and dyspnea
with SARS-CoV-2 infection, an effective COVID-19 screening program may enable early diagnosis and
proper treatment in order to significantly reduce the risk of disease and mortality [157]. A study of
18 cancer patients from a nationwide 2007 COVID-19 cohort showed that cancer patients were at greater
risk of serious adverse incidents than non-cancer patients [104]. Another study with 28 cancer patients
showed that lung cancer patients developed severe baseline lung function, endurance, and anoxia
more rapidly with COVID-19 [85]. Based on these relevant findings, appropriate management of
lung cancer patients remain unclear, and a better understanding is needed to reduce the number of
cancer-infectious related targets throughout the COVID-19 era. Although it seems logical to postpone
or delay the delivery of cancer treatment in certain cases, the eventual outcomes, risk, or benefits of
those changes are still to be assessed.
A very recent study by Kong (2020), analyzed the differential expression of ACE-2 and TMPRSS2
in two common types of lung cancers, lung adenocarcinoma (LUAD) and lung squamous cell
carcinoma (LUSC), and their correlation with prognosis and SARS-CoV-2 infection [99]. In this study,
gene expression of TMPRSS2 was reduced in LUSC as compared to LUAD; however, expression of
ACE-2 was enhanced in LUAD but not in LUSC [99]. Furthermore, in comparison to ACE-2 expression
in normal lung tissue, TMPRSS2 expression was enhanced; this differential expression was more
profound in LUAD and significantly correlated with pathological stages and subtypes [99]. The study
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also suggested that lung cancer patients, especially LUAD, were more prone to develop COVID-19
disease [99]. Data using the lung cancer cell line, Calu-3 cells transfected with SARS-CoV as wel as
lung cancer samples showed less elevated TMPRSS2 expression than ACE-2 expression, which was
highly expressed [158].
The direct implications of ACE-2 inhibition in COVID-19 patients with lung cancer remain elusive,
and clinical evidence is desperately needed to determine the relative benefits and risks associated with
usage of these medications [60]. Nonetheless, modulation of ACE-2 in patients already infected by
SARS-CoV-2 may be an effective therapeutic option in addressing the viral-mediated RAS imbalance
and is currently under investigation in several clinical trials.
5. Emerging Therapeutic Approaches for ACE-2
Pharmacological RAS blockade agents, angiotensin receptor blockers (ARBs), in particular, are capable
of modulating both systemic and tissue RAS, simultaneously increasing ACE-2 expression and activity
in experimental models. Generally, mechanisms behind the augmentation of ACE-2 mRNA levels by
ACE inhibitors and ARBs require further characterization. ARBs enhance the expression/activity of Ang
(1-7) that is tissue-defensive and prevents Ang-II-induced acute lung injury and inflammation [159,160].
To date, however, no compelling scientific data have been found linking ACE inhibitors and/or ARBs with
the incidence and mortality of COVID-19 [161].
While, AT1R inactivation with antagonists has successfully reduced tumor growth of cancers
including gastric, colorectal, prostate, renal, breast, and NSCLCs [162–165]. Current pharmacotherapies
aim to achieve multilevel RAS inhibition through distinct modes of action. Although ACE-2 is not the
direct cellular target of these therapies, Ace-2 gene transcription, translation, and ultimately catalytic
activities are modified due to the intricate nature of the RAS [60]. Blocking the ACE/Ang-II/AT1R axis
through modulating the actions of Ang-II potentiates the effects of ACE-2 as the endogenous RAS
counter-regulator based on the fact that Ang-II can regulate ACE-2 expression through AT1R [166].
The SARS and SARS-CoV-2 coincidences using the ACE-2 receptor allow the possibility of using and
applying the detailed investigations of coronavirus entry to treat COVID-19. According to literature
on SARS, various possible ACE-2 blocking techniques have proven successful in avoiding infection in
SARS models which can be effective against COVID-19 (Figure 2).
On the other hand, one approach is to provide an ACE-2 binding agent to patients where the
host ACE-2 protein is not altered thereby diminishing the risk associated with this therapeutic agent.
Two recognized solutions are available for ACE-2 binding agents. The first one is utilizing the tiny
SARS-S receptor-binding domain (RBD), the main domain that attaches to the ACE-2 receptor during
entry [167]. Conversely, the RBD protein may be added to the expanded circulation fragment of
Fc, which was developed as an analogous of 212 amino acid domains from MERS. It is known that
if the RBD-Fc fusion attaches to human cells, the cytotoxicity of Fc domain will be eliminated by
introducing mutations to disable Fc receptor binding [168]. A second approach is to supply an antibody
that binds to the ACE-2 receptor to avoid infection with SARS-CoV-2. This approach has shown
that the viral entry and replication are effectively blocked [169]. Although no ACE-2 sequence of
antibodies is reported, monoclonal and associated hybridoma sequences can be coned. This approach
is better than S-protein neutralization as no possible viral escape from ACE binding antibodies could
be detected [170]. A single chain-variable-fragment (scFv) that binds to ACE-2 can be used through
neutralization to increase the concentration of anti-ACE-2 upon local administration in infected lungs.
Administration of SARS RBD-Fc fusion protein in murine lung tissues exacerbates the alveolar after
ACE-2 interactions, which usually mitigate acute pulmonary injury [64]. This indicates the importance
of using ACE-2 binding strategy early-on during infection or as a prophylaxis to prevent the initial
viral infection. Collectively, these possible complications will need to be examined in clinical research.
While, it is clear that a far more effective approach would be to build an antibody-like agent that
would attach to the coronavirus itself rather than protect the cells from infection. With this approach,
it is recommended to use a soluble form of the ACE-2 receptor that will bind to the SARS-CoV-2
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protein to neutralize the virus. Soluble ACE-2 receptor has been shown to prevent SARS from infecting
cells in culture [169]. In order to use ACE-2 to treat COVID-19 patients, it is preferable to treat
patients with soluble ACE-2 fused to Fc immunoglobulin domain (ACE-2-Fc). Previous studies have
shown that fusion of human IgG1 to an ACE-2 extracellular domain was successful in neutralizing
SARS-coronavirus in-vitro [171]. This study also offers proof that ACE-2-Fc could likewise inhibit
SARS-CoV-2 in-vitro and possibly in patients.
Finally, it is evident that more focus has been given to ACE-2, only a few studies have considered
TMPRSS2; suggesting that more research need to focus on TMPRSS2 which has a vital role along with
ACE-2 in SARS-CoV-2 infection and can pave the way for therapeutic intervention in COVID–19.
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Figure 2. Potential therapeutic approaches to address ACE-2-mediated COVID-19 following
SARS-CoV-2 infection. ACE-2 converts Ang-I to Ang (1-7) which acts through Mas receptor to protect
from acute lung failure. On the other hand, the “spike” attachment protein for the current S RS-CoV-2
coronavirus uses the cellular attach ent factor, ( E-2) and requires T PRSS2 cell protease for
activation. Therapeutic approaches include TMPRSS2 inhibitors (Camostat and Nafamostat) that inhibit
priming of the spike protein as wel as blocking the surface ACE-2 receptor using anti-ACE-2 antibody or
peptides which decrease viral entry into cells through competitively binding with SARS-CoV-2 thereby
reducing viral spread a d protecting the lungs from i jury throu h its unique enzymatic function.
6. Emerging Therapeutic Approaches for TMPRSS2
Of the various factors regulating SARS-CoV-2 entry, TMPRSS2 is the most favorable candidate for
transcriptional inhibition as TMPRSS2 is required for SARS-CoV-2 entry to host cells and its expression
levels are linked with lung disease severity.
In this context, blocking TMPRSS2 enables targeting influenza virus along with coronavirus,
in addition to other respiratory viruses (Figure 2). TMPRSS2 enhances fusion proteins of some
paramyxoviruses such as metapneumovirus [82], trypsin-dependent parainfluenza subtypes and Sendai
virus [172]. Due to the acute role of TMPRSS2 as a host cell factor for viral infections [27,28,92,158],
serine protease inhibitors (Camostat, Nafamostat, and Leupeptin) have been implicated in the antiviral
therapeutic strategy targeting TMPRSS2 with high antiviral activities [92,173,174]. Along with
camostat, aprotinin also blocks replication of the influenza virus in the human airway epithelial cells
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and releases cytokines (IL-6 and TNF-α) into cell supernatants [135]. The serine protease inhibitor,
Camostat mesylate, commonly known as Foypan, is an approved drug in Japan for use in pancreatic
inflammation; it is found to inhibit TMPRSS2 activity [92,158], suggesting use of the compound or
related ones with possibly enhanced antiviral activity [174] might be considered as a therapeutic target
for SARS-CoV-2-infected patients (Figure 2). Furthermore, in-vivo data showed efficiency of camostat
in preventing mice from developing lethal infection by SARS coronavirus [92].
Nafamostat mesylate, also known as Fusan, is another serine protease inhibitor that acts as
anti-coagulant with few anti-cancer and anti-viral properties [174]. Very recently, Nafamostat was
found to inhibit fusion of the viral envelope with host cell surface membranes, the initial step in
SARS-CoV-2 infection [175], thus, suggesting efficacy in inhibiting SARS-CoV-2 virus entry and spread
(Figure 2). In comparison to Camostat, Nafamostat blocked SARS-CoV-2 S protein-initiated fusion at a
concentration less than one-tenth as needed for Camostat, indicating Nafamostat as the most effective
drug against SARS-CoV-2 S protein-initiated fusion in clinical practice [175]. Since, Nafamostat is
administered intravenously; it is assumed that blood concentration of Nafamostat post-administration
would exceed the experimental concentration to block SARS-CoV-2 S protein-initiated fusion [175].
In contrast, Camostat is orally administered and hence, it is indicated that blood levels may be inferior
to Nafamostat, suggesting Nafamostat to have a higher preventive role in SARS-CoV-2 upon entering
human cells [175].
Also, earlier studies analyzed the synergistic effect of airway protease inhibitors with
conventional antiviral drugs to reduce the risk of resistance. Synergy of serine protease inhibitor,
BAPA (benzylsulfonyl-d-Arg-Pro-4-amidinobenzylamide) with oseltamivir significantly inhibited
replication of influenza virus in human airway epithelial cells at lower concentrations in comparison
to treatment with each inhibitor alone [176].
Several FDA approved drugs are involved in blocking host proteins which regulate entry of
SARS-CoV-2 into host cells. Of these, the estrogen-related compounds (estradiol and genistein) and
the androgen receptor antagonist (enzalutamide) block TMPRSS2 [177–179], which is required for
SARS-CoV-2 spike protein priming and appear to be the most promising repurposing candidates for
symptom amelioration in COVID-19 patients. Commonly approved drugs which are involved in the
same pathway can also be plausible candidates to transcriptionally suppress TMPRSS2, including
dutasteride and finasteride [180,181]. Furthermore, in-vivo study using female mice-infected with
SARS-CoV showed that treatment involving ovariectomy or estrogen receptor antagonists, enhanced
TMPRSS2 expression resulting in lethality [182]. Finally, and since there is a lack of antiviral medication
for these paramyxoviruses and coronaviruses, broader-acting airway protease inhibitors are needed to
pave the way for therapeutic intervention.
7. Conclusions
As of 7 July 2020, there are more than 11.5 million infected people with SARS-CoV-2 virus,
that caused around half a million deaths with an excess of 6.6 million reported recoveries [183].
Meanwhile, it is evident that numerous questions regarding the coronavirus infection and pathogenesis
remain unanswered. Indeed, patients with cancer, particularly lung cancer, are at a higher risk of
developing severe complications following their infection by SARS-CoV-2, hence important measures
have to be considered to minimize infection risk for this group of patients. Moreover, extensive
studies on molecular and cellular levels are needed to understand the mechanism of action of this
virus which may allow the development of new therapies to manage the infection of SARS-CoV-2;
specially since there is no vaccine available to prevent this viral infection. In this context, structural
experiments of SARS-CoV-2 S-Proteins binding to ACE-2 and TMPRSS2, the key entry genes in
infected cells, should contribute to better understanding of the structural/functional correlations of
this novel coronavirus that would enable targeted therapies via blocking or manipulating one or both
of them. On the other hand, developing in-vitro and in-vivo models including conditional double
transgenic/knockout of ACE-2 and TMPRSS2 could be one of best models to understand to role of these
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genes in the infection process which also can help to develop new therapies based on the shutdown of
one or both of these genes.
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